Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | TK2 | O00142 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL778861 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL4201980 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL16189745 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12286396 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2922181 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL7882259 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL3437225 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL23486 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL21078835 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL3437224 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181147-B | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2024-04-02 | — | — | CN | claimed |
| CN-115181147-A | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2022-10-14 | — | — | CN | claimed |
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | claimed |
| EP-4688781-A1 | METHODS AND REAGENTS FOR SYNTHESIZING HALOALDEHYDES, AND USES THEREOF | Simon Fraser University (CA) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201390-A1 | METHODS AND REAGENTS FOR SYNTHESIZING HALOALDEHYDES, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024201393-A1 | METHODS FOR THE SYNTHESIS OF NUCLEOSIDE ANALOGUES AND NUCLEOSIDES ANALOGUES DERIVED THEREFROM | SIMON FRASER UNIVERSITY (CA) | 2024-10-03 | — | — | WO | disclosed |
| CN-115181147-B | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2024-04-02 | — | — | CN | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | SIMON FRASER UNIVERSITY (CA) | 2023-04-27 | — | — | US | disclosed |
| CN-115667280-A | Method and reagent for synthesizing nucleoside and analogue thereof | 西蒙弗雷泽大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-115181147-A | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2022-10-14 | — | — | CN | disclosed |
| WO-2021030763-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-5449664-A | Nucleosides | SYNTEX (U.S.A.) INC. (US) | 1995-09-12 | — | — | US | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
| EP-0457326-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| EP-0013625-B1 | SOLUBILIZED THYMIDINE COMPOSITION AND METHOD OF PRODUCING SAME | Marcus, Israel (IL) | 1982-11-17 | — | — | EP | disclosed |
| US-3975374-A | Process for preparing 2-thiouracil nucleosides | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | NUDT1, ADAR, APRT | TK1 199/4885LMNA 1420/4885SMN1; SMN2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.